URGN: Zusduri's demand-driven growth and expanding adoption set the stage for major pipeline milestones
RTGel technology underpins a strong launch for Zusduri, with revenue up 73% and growing physician adoption, especially in community practices. Pipeline progress includes UGN-103 and UGN-501, with key data and regulatory milestones expected over the next 12—18 months.Based on UroGen Pharma Ltd. [URG…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.